MovDisordV3, PascalFrancis, Corpus, bibRecord, 000312

Pharmacologic Approaches to the Treatment of Huntington's Disease

Identifieur interne : 000312 ( PascalFrancis/Corpus ); précédent : 000311; suivant : 000313

Pharmacologic Approaches to the Treatment of Huntington's Disease

Auteurs : Charles S. Venuto ; Andrew Mcgarry ; QING MA ; Karl Kieburtz

Source :

Movement disorders [ 0885-3185 ] ; 2012.

RBID : Pascal:12-0106476

Descripteurs français

Pascal (Inist)
- Chorée de Huntington, Hyperkinésie, Syndrome choréique, Pathologie du système nerveux, Voie abord, Traitement.

English descriptors

KwdEn :
- Chorea, Huntington disease, Hyperkinesia, Nervous system diseases, Surgical approach, Treatment.

Abstract

Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder characterized by chorea, cognitive impairment, and behavioral disturbances. Despite advances in diagnosis and improved understanding of HD, treatment remains difficult due to challenging symptoms and a paucity of approved therapeutic interventions. Nonpharmacologic and pharmacologic strategies have been evaluated; regarding the latter, over 80 agents of various classes have been investigated in clinical trials or examined in case reports. Symptomatic treatment, however, is generally confined to antidopaminergic agents for motor dysfunction and antidepressants for mood disorders, while treatment for cognitive dysfunction remains vacant. Several different mechanisms to modify symptoms and disease progression have been targeted in clinical trials. This article reviews some of the more common pharmacologic treatments used for HD, discusses data regarding suboptimal agents that have been tested, and surveys treatments under investigation.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 27`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Pharmacologic Approaches to the Treatment of Huntington's Disease`
A11	`01`	`1`		`@1 VENUTO (Charles S.)`
A11	`02`	`1`		`@1 MCGARRY (Andrew)`
A11	`03`	`1`		`@1 QING MA`
A11	`04`	`1`		`@1 KIEBURTZ (Karl)`
A14	`01`			`@1 Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry @2 Rochester, New York @3 USA @Z 1 aut. @Z 3 aut. @Z 4 aut.`
A14	`02`			`@1 Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo @2 Buffalo, New York @3 USA @Z 1 aut. @Z 3 aut.`
A14	`03`			`@1 Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences @2 Buffalo, New York @3 USA @Z 1 aut. @Z 3 aut.`
A14	`04`			`@1 Department of Neurology, University of Rochester School of Medicine and Dentistry @2 Rochester, New York @3 USA @Z 2 aut. @Z 4 aut.`
A20				`@1 31-41`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000508687520050`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 131 ref.`
A47	`01`	`1`		`@0 12-0106476`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder characterized by chorea, cognitive impairment, and behavioral disturbances. Despite advances in diagnosis and improved understanding of HD, treatment remains difficult due to challenging symptoms and a paucity of approved therapeutic interventions. Nonpharmacologic and pharmacologic strategies have been evaluated; regarding the latter, over 80 agents of various classes have been investigated in clinical trials or examined in case reports. Symptomatic treatment, however, is generally confined to antidopaminergic agents for motor dysfunction and antidepressants for mood disorders, while treatment for cognitive dysfunction remains vacant. Several different mechanisms to modify symptoms and disease progression have been targeted in clinical trials. This article reviews some of the more common pharmacologic treatments used for HD, discusses data regarding suboptimal agents that have been tested, and surveys treatments under investigation.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Chorée de Huntington @5 01`
C03	`01`	`X`	`ENG`	`@0 Huntington disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Corea Huntington @5 01`
C03	`02`	`X`	`FRE`	`@0 Hyperkinésie @5 02`
C03	`02`	`X`	`ENG`	`@0 Hyperkinesia @5 02`
C03	`02`	`X`	`SPA`	`@0 Hiperquinesia @5 02`
C03	`03`	`X`	`FRE`	`@0 Syndrome choréique @5 03`
C03	`03`	`X`	`ENG`	`@0 Chorea @5 03`
C03	`03`	`X`	`SPA`	`@0 Corea síndrome @5 03`
C03	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 04`
C03	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 04`
C03	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 04`
C03	`05`	`X`	`FRE`	`@0 Voie abord @5 09`
C03	`05`	`X`	`ENG`	`@0 Surgical approach @5 09`
C03	`05`	`X`	`SPA`	`@0 Vía abordaje @5 09`
C03	`06`	`X`	`FRE`	`@0 Traitement @5 10`
C03	`06`	`X`	`ENG`	`@0 Treatment @5 10`
C03	`06`	`X`	`SPA`	`@0 Tratamiento @5 10`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie héréditaire @5 40`
C07	`04`	`X`	`ENG`	`@0 Genetic disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad hereditaria @5 40`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 43`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 43`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 43`
C07	`07`	`X`	`FRE`	`@0 Trouble de la psychomotricité @5 44`
C07	`07`	`X`	`ENG`	`@0 Psychomotor disorder @5 44`
C07	`07`	`X`	`SPA`	`@0 Trastorno psicomotriz @5 44`
C07	`08`	`X`	`FRE`	`@0 Mouvement involontaire @5 45`
C07	`08`	`X`	`ENG`	`@0 Involuntary movement @5 45`
C07	`08`	`X`	`SPA`	`@0 Movimiento involuntario @5 45`
N21				`@1 079`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 12-0106476 INIST
ET :	Pharmacologic Approaches to the Treatment of Huntington's Disease
AU :	VENUTO (Charles S.); MCGARRY (Andrew); QING MA; KIEBURTZ (Karl)
AF :	Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry/Rochester, New York/Etats-Unis (1 aut., 3 aut., 4 aut.); Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo/Buffalo, New York/Etats-Unis (1 aut., 3 aut.); Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences/Buffalo, New York/Etats-Unis (1 aut., 3 aut.); Department of Neurology, University of Rochester School of Medicine and Dentistry/Rochester, New York/Etats-Unis (2 aut., 4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2012; Vol. 27; No. 1; Pp. 31-41; Bibl. 131 ref.
LA :	Anglais
EA :	Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder characterized by chorea, cognitive impairment, and behavioral disturbances. Despite advances in diagnosis and improved understanding of HD, treatment remains difficult due to challenging symptoms and a paucity of approved therapeutic interventions. Nonpharmacologic and pharmacologic strategies have been evaluated; regarding the latter, over 80 agents of various classes have been investigated in clinical trials or examined in case reports. Symptomatic treatment, however, is generally confined to antidopaminergic agents for motor dysfunction and antidepressants for mood disorders, while treatment for cognitive dysfunction remains vacant. Several different mechanisms to modify symptoms and disease progression have been targeted in clinical trials. This article reviews some of the more common pharmacologic treatments used for HD, discusses data regarding suboptimal agents that have been tested, and surveys treatments under investigation.
CC :	002B17; 002B17G
FD :	Chorée de Huntington; Hyperkinésie; Syndrome choréique; Pathologie du système nerveux; Voie abord; Traitement
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Maladie héréditaire; Pathologie du système nerveux central; Trouble neurologique; Trouble de la psychomotricité; Mouvement involontaire
ED :	Huntington disease; Hyperkinesia; Chorea; Nervous system diseases; Surgical approach; Treatment
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Genetic disease; Central nervous system disease; Neurological disorder; Psychomotor disorder; Involuntary movement
SD :	Corea Huntington; Hiperquinesia; Corea síndrome; Sistema nervioso patología; Vía abordaje; Tratamiento
LO :	INIST-20953.354000508687520050
ID :	12-0106476

Links to Exploration step

Pascal:12-0106476

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Pharmacologic Approaches to the Treatment of Huntington's Disease</title>
<author><name sortKey="Venuto, Charles S" sort="Venuto, Charles S" uniqKey="Venuto C" first="Charles S." last="Venuto">Charles S. Venuto</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo</s1>
<s2>Buffalo, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences</s1>
<s2>Buffalo, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcgarry, Andrew" sort="Mcgarry, Andrew" uniqKey="Mcgarry A" first="Andrew" last="Mcgarry">Andrew Mcgarry</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Qing Ma" sort="Qing Ma" uniqKey="Qing Ma" last="Qing Ma">QING MA</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo</s1>
<s2>Buffalo, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences</s1>
<s2>Buffalo, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0106476</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0106476 INIST</idno>
<idno type="RBID">Pascal:12-0106476</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000312</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Pharmacologic Approaches to the Treatment of Huntington's Disease</title>
<author><name sortKey="Venuto, Charles S" sort="Venuto, Charles S" uniqKey="Venuto C" first="Charles S." last="Venuto">Charles S. Venuto</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo</s1>
<s2>Buffalo, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences</s1>
<s2>Buffalo, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mcgarry, Andrew" sort="Mcgarry, Andrew" uniqKey="Mcgarry A" first="Andrew" last="Mcgarry">Andrew Mcgarry</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Qing Ma" sort="Qing Ma" uniqKey="Qing Ma" last="Qing Ma">QING MA</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo</s1>
<s2>Buffalo, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences</s1>
<s2>Buffalo, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chorea</term>
<term>Huntington disease</term>
<term>Hyperkinesia</term>
<term>Nervous system diseases</term>
<term>Surgical approach</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Chorée de Huntington</term>
<term>Hyperkinésie</term>
<term>Syndrome choréique</term>
<term>Pathologie du   système nerveux</term>
<term>Voie abord</term>
<term>Traitement</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder characterized by chorea, cognitive impairment, and behavioral disturbances. Despite advances in diagnosis and improved understanding of HD, treatment remains difficult due to challenging symptoms and a paucity of approved therapeutic interventions. Nonpharmacologic and pharmacologic strategies have been evaluated; regarding the latter, over 80 agents of various classes have been investigated in clinical trials or examined in case reports. Symptomatic treatment, however, is generally confined to antidopaminergic agents for motor dysfunction and antidepressants for mood disorders, while treatment for cognitive dysfunction remains vacant. Several different mechanisms to modify symptoms and disease progression have been targeted in clinical trials. This article reviews some of the more common pharmacologic treatments used for HD, discusses data regarding suboptimal agents that have been tested, and surveys treatments under investigation.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>27</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Pharmacologic Approaches to the Treatment of Huntington's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>VENUTO (Charles S.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MCGARRY (Andrew)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>QING MA</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>KIEBURTZ (Karl)</s1>
</fA11>
<fA14 i1="01"><s1>Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo</s1>
<s2>Buffalo, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences</s1>
<s2>Buffalo, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, University of Rochester School of Medicine and Dentistry</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>31-41</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000508687520050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>131 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0106476</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder characterized by chorea, cognitive impairment, and behavioral disturbances. Despite advances in diagnosis and improved understanding of HD, treatment remains difficult due to challenging symptoms and a paucity of approved therapeutic interventions. Nonpharmacologic and pharmacologic strategies have been evaluated; regarding the latter, over 80 agents of various classes have been investigated in clinical trials or examined in case reports. Symptomatic treatment, however, is generally confined to antidopaminergic agents for motor dysfunction and antidepressants for mood disorders, while treatment for cognitive dysfunction remains vacant. Several different mechanisms to modify symptoms and disease progression have been targeted in clinical trials. This article reviews some of the more common pharmacologic treatments used for HD, discusses data regarding suboptimal agents that have been tested, and surveys treatments under investigation.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Chorée de Huntington</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Huntington disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Corea Huntington</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Hyperkinésie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Hyperkinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Hiperquinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Syndrome choréique</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chorea</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Corea síndrome</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Voie abord</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Surgical approach</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Vía abordaje</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie héréditaire</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Genetic disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad hereditaria</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Trouble de la psychomotricité</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Psychomotor disorder</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Trastorno psicomotriz</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>45</s5>
</fC07>
<fN21><s1>079</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 12-0106476 INIST</NO>
<ET>Pharmacologic Approaches to the Treatment of Huntington's Disease</ET>
<AU>VENUTO (Charles S.); MCGARRY (Andrew); QING MA; KIEBURTZ (Karl)</AU>
<AF>Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry/Rochester, New York/Etats-Unis (1 aut., 3 aut., 4 aut.); Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo/Buffalo, New York/Etats-Unis (1 aut., 3 aut.); Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences/Buffalo, New York/Etats-Unis (1 aut., 3 aut.); Department of Neurology, University of Rochester School of Medicine and Dentistry/Rochester, New York/Etats-Unis (2 aut., 4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2012; Vol. 27; No. 1; Pp. 31-41; Bibl. 131 ref.</SO>
<LA>Anglais</LA>
<EA>Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder characterized by chorea, cognitive impairment, and behavioral disturbances. Despite advances in diagnosis and improved understanding of HD, treatment remains difficult due to challenging symptoms and a paucity of approved therapeutic interventions. Nonpharmacologic and pharmacologic strategies have been evaluated; regarding the latter, over 80 agents of various classes have been investigated in clinical trials or examined in case reports. Symptomatic treatment, however, is generally confined to antidopaminergic agents for motor dysfunction and antidepressants for mood disorders, while treatment for cognitive dysfunction remains vacant. Several different mechanisms to modify symptoms and disease progression have been targeted in clinical trials. This article reviews some of the more common pharmacologic treatments used for HD, discusses data regarding suboptimal agents that have been tested, and surveys treatments under investigation.</EA>
<CC>002B17; 002B17G</CC>
<FD>Chorée de Huntington; Hyperkinésie; Syndrome choréique; Pathologie du   système nerveux; Voie abord; Traitement</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Maladie héréditaire; Pathologie du   système nerveux central; Trouble neurologique; Trouble de la psychomotricité; Mouvement involontaire</FG>
<ED>Huntington disease; Hyperkinesia; Chorea; Nervous system diseases; Surgical approach; Treatment</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Genetic disease; Central nervous system disease; Neurological disorder; Psychomotor disorder; Involuntary movement</EG>
<SD>Corea Huntington; Hiperquinesia; Corea síndrome; Sistema nervioso patología; Vía abordaje; Tratamiento</SD>
<LO>INIST-20953.354000508687520050</LO>
<ID>12-0106476</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000312 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000312 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:12-0106476
   |texte=   Pharmacologic Approaches to the Treatment of Huntington's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Pharmacologic Approaches to the Treatment of Huntington's Disease

Pharmacologic Approaches to the Treatment of Huntington's Disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri